Previous 10 | Next 10 |
2023-06-01 11:28:37 ET Summary Lexicon Pharmaceuticals received FDA approval to market its heart failure drug Inpefa, as well as a broad label compared to rivals like AstraZeneca's Farxiga and Lilly's Jardiance. The company faces significant challenges in marketing Inpefa against ...
2023-06-01 10:07:16 ET Gainers: Nanobiotix ( NBTX ) +17% . Veeva Systems ( VEEV ) +13% . Biohaven ( BHVN ) +12% . Rockwell Medical ( RMTI ) +11% . Quipt Home Medical ( QIPT ) +9% . Losers: Lexicon Pharmaceuticals ( LXRX ...
2023-06-01 08:30:01 ET Okta OKTA -19% after Q1earning release . Lexicon Pharmaceuticals ( LXRX ) -18% announces pricing of $125 Million public offering and concurrent private placement. C3.ai AI -17% after Q4 earning release . Victoria's Secret &...
THE WOODLANDS, Texas, June 01, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced the pricing of its previously announced underwritten public offering of 23,924,705 shares of its common stock, par value $0.001. The shares of c...
2023-05-31 17:19:57 ET Gainers: Red Cat Holdings ( RCAT ) +62% . Paltalk ( PALT ) +19% . Viant Technology ( DSP ) +9% . Meta Materials ( MMAT ) +9% . VIZIO Holding ( VZIO ) +8% . Losers: Lexicon Pharmaceutical...
THE WOODLANDS, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“ Lexicon ”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par ...
2023-05-30 13:14:47 ET Gainers: Atento ( ATTO ) +92% . Wearable Devices ( WLDS ) +86% . T2 Biosystems ( TTOO ) +55% . Arlington Asset Investment ( AAIC ) +45% . Equitrans Midstream Corporation ( ETRN ) +36% . The Glimpse Grou...
2023-05-30 08:34:33 ET Arlington Asset Investment ( AAIC ) +53% Announce Definitive Merger Agreement. Equitrans Midstream ( ETRN ) +33% . HeartBeam ( BEAT ) +28% Enters into Strategic Alliance Agreement with Samsung. Wearable Devices (...
INPEFA granted broad label across full range of left ventricular ejection fraction, including HFpEF and HFrEF, and for patients with or without diabetes INPEFA reduced the risk of total occurrence of cardiovascular death, hospitalization for heart failure, and urgent heart failure v...
2023-05-26 08:34:32 ET Onfolio Holdings ( ONFO ) +62% Completes Development of Generative AI Search Tool. Elevation Oncology ( ELEV ) +58% . Quhuo Limited ( QH ) +37% Sector Exceeded RMB12 Million in Sales During the Labor Day Holiday, Achieving Impre...
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...